Recipient: Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (Leibniz Institute on Ageing – Fritz-Lipmann Institute)
Funding: GO-Bio initial conceptual phase 4 (01/10/2023 to 30/09/2024, EUR 96,150.00)

Project description:

The energy centres of our cells, the mitochondria, perform vital functions. If these functions are disrupted diseases for which there are often no effective therapies can arise. Current approaches to treatment are primarily intended to alleviate the symptoms of the diseases. In contrast, this project aims to improve metabolic functions with the help of so-called hydrogen sulphide donors.

Preliminary studies have shown that a specific hydrogen sulphide donor is able to support mitochondrial function. This support could have a positive influence on the course of the disease. A major advantage of this specific hydrogen sulphide donor is its high availability in the body and its exceptional behaviour during effective absorption into the body. These features may increase the efficacy and safety of potential therapies. The efficacy of the active ingredient will in the future be further investigated in order to develop a drug and, if successful, revolutionise the treatment of mitochondrial diseases. In the upcoming exploratory phase a concept for the best possible utilisation of the active ingredient is to be developed. To this end an IP strategy will be developed, the market and competition will be analysed, an implementation plan for the subsequent feasibility phase will be drawn up and preliminary investigations will be carried out.